MedTrace Logo

Study for Beinaglutide Versus Glargine Therapy in Glycemic Variability of Type 2 Diabetes Mellitus

NCT03829891 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-01-19

No results posted yet for this study

Summary

The investigators aimed to assess the efficacy and safety of Beinaglutide versus glargine , in individuals with type 2 diabetes who did not achieve adequate glycaemic control with oral antidiabetic drug.

Conditions

Interventions

DRUG

Beinaglutide

1. Beinaglutide for 8 weeks, 2. Beinaglutide + glargine for 8 weeks(only the subjects whose blood glucose not reach the standard )

DRUG

glargine

1. Glargine for 8 weeks, 2. Glargine+Beinaglutide for 8 weeks(only the subjects whose blood glucose not reach the standard )

Sponsors & Collaborators

  • Xijing Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-07
Primary Completion
2019-12-31
Completion
2020-12-04

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03829891 on ClinicalTrials.gov